No insider purchase over the last 90 days. The latest was filed 15 Jun 2026.
Every trade that managers of CervoMed Inc. disclose to SEC (Form 4) is tracked on this page. The last twelve months, up to 18 October 2026, brought 11 filings signed by 5 insiders.
No insider sold shares on the market over the period. Instead, the filings list 11 purchases totalling €406k, made by 5 insiders. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 3 senior executives, 1 finance chief and 1 chief executive. At €79k, the purchase published on 19 November 2025 by Alam John J is the largest of the period.
In all, 10 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 15 June 2026, 125 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 11 filings, this issuer sits below that mark. Looking back to 2016, when coverage begins, insiders filed 14 purchases and no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate CervoMed Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$15.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 43 declarations
CervoMed Inc. is a company focused on developing treatments for neurodegenerative diseases. It is listed on the XNAS market.
Purchases our model currently ranks for the recommendations list.
All recommendations